AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25928739 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 2 (attendance incentives and tailored support)
Number of subjects: 1300
Study 25928739 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1300
Study 23615633 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with telmisartan (80 mg/d) and aliskiren (300 mg/d)
Number of subjects: 18
Study 23615633 — intervention group
Group type: COMPARATOR
Intervention: Combination treatment with telmisartan (160 mg/d) alone
Number of subjects: 18
Study 23615633 — intervention group
Group type: COMPARATOR
Intervention: Combination treatment with telmisartan (80 mg/d) and eplerenone (50 mg/d)
Number of subjects: 18
Study 21840177 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (twice daily for 14 days)
Number of subjects: 20
Study 21840177 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily for 14 days)
Number of subjects: 20
Study 19377488 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg tadalafil
Number of subjects: 1046
Study 19377488 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg tadalafil
Number of subjects: 1046
Study 19377488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1046
Study 17125930 — intervention group
Group type: EXPERIMENTAL
Intervention: l-Arg (400 mg/kg/day)
Number of subjects: 47
Study 17125930 — intervention group
Group type: EXPERIMENTAL
Intervention: l-Arg (200 mg/kg/day)
Number of subjects: 47
Study 17125930 — intervention group
Group type: COMPARATOR
Intervention: Control (no l-Arg supplementation)
Number of subjects: 47
Study 15352969 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous parecoxib 40 mg followed by oral valdecoxib 40 mg qd
Number of subjects: 0
Study 15352969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11435054 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium 0.03 mg/kg
Number of subjects: 45
Study 11435054 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 0.5 mL
Number of subjects: 45
Study 11435054 — intervention group
Group type: COMPARATOR
Intervention: Gallamine 0.04 mg/kg
Number of subjects: 45
Study 9764260 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife home visiting programme (Group A)
Number of subjects: 408
Study 9764260 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 408
Study 7878625 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirulog 1.0 mg/kg subcutaneously
Number of subjects: 10
Study 7878625 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirulog 0.6 mg/kg as a 15 min intravenous infusion
Number of subjects: 10
Study 7878625 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirulog (both regimens)
Number of subjects: 10
Study 7878625 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional anticoagulants)
Number of subjects: 10
Study 3067338 — intervention group
Group type: EXPERIMENTAL
Intervention: Olsalazine, 2 g/day
Number of subjects: 126
Study 3067338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 29067495 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) 162 mg subcutaneously
Number of subjects: 28
Study 29067495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 29067495 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 28
Study 26541724 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Sleeve Gastrectomy (LSG)
Number of subjects: 54
Study 26541724 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Greater Curvature Plication (LGCP)
Number of subjects: 54
Study 24964511 — intervention group
Group type: EXPERIMENTAL
Intervention: Saunders lumbar traction
Number of subjects: 140
Study 24964511 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological treatment
Number of subjects: 140
Study 22949743 — intervention group
Group type: EXPERIMENTAL
Intervention: Promoting First Relationships (PFR) intervention for caregivers
Number of subjects: 210
Study 22949743 — intervention group
Group type: COMPARATOR
Intervention: Comparison condition
Number of subjects: 210
Study 20834039 — intervention group
Group type: EXPERIMENTAL
Intervention: Laquinimod 0.3/0.6 mg doses
Number of subjects: 257
Study 20834039 — intervention group
Group type: EXPERIMENTAL
Intervention: Laquinimod 0.6 mg
Number of subjects: 257
Study 20834039 — intervention group
Group type: COMPARATOR
Intervention: Placebo to Laquinimod 0.3/0.6 mg
Number of subjects: 257
Study 20834039 — intervention group
Group type: EXPERIMENTAL
Intervention: Laquinimod 0.6 mg/day
Number of subjects: 257
Study 18215593 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily
Number of subjects: 145
Study 18215593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 15998706 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (50 mg per day)
Number of subjects: 38
Study 15998706 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamterene (50 mg per day)
Number of subjects: 38
Study 12860942 — intervention group
Group type: COMPARATOR
Intervention: Oxaliplatin at 130 mg/m2 every 3 weeks
Number of subjects: 37
Study 10397122 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive contrast agent (27 patients)
Number of subjects: 57
Study 10397122 — intervention group
Group type: COMPARATOR
Intervention: Negative contrast agent (30 patients)
Number of subjects: 57
Study 8814682 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg
Number of subjects: 378
Study 8814682 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 10 mg
Number of subjects: 378
Study 8814682 — intervention group
Group type: COMPARATOR
Intervention: Megestrol acetate
Number of subjects: 378
Study 1804746 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule A: amiodarone infusion at a rate of 1.5 mg/kg/h up to two hours after restoration of sinus rhythm or to a maximum dose of 1200 mg
Number of subjects: 28
Study 1804746 — intervention group
Group type: COMPARATOR
Intervention: Schedule B: single amiodarone infusion of 300 mg over 15 minutes, followed by a 300 mg maintenance dose over three hours
Number of subjects: 28
Study 6300213 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigen
Number of subjects: 27
Study 6300213 — intervention group
Group type: COMPARATOR
Intervention: Buffer
Number of subjects: 27
Study 31858754 — intervention group
Group type: EXPERIMENTAL
Intervention: Anyfusion® method
Number of subjects: 22
Study 31858754 — intervention group
Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 22
Study 30352746 — intervention group
Group type: COMPARATOR
Intervention: Homeopathic vaccine
Number of subjects: 150
Study 30352746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 30352746 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Tdap and MMR vaccines
Number of subjects: 150
Study 27846256 — intervention group
Group type: EXPERIMENTAL
Intervention: rAd35-EnvA 1010 PU
Number of subjects: 25
Study 27846256 — intervention group
Group type: EXPERIMENTAL
Intervention: rAd35-EnvA 1011 PU
Number of subjects: 25
Study 27846256 — intervention group
Group type: EXPERIMENTAL
Intervention: rAd5-EnvA 1010 PU
Number of subjects: 25
Study 27846256 — intervention group
Group type: EXPERIMENTAL
Intervention: rAd35-EnvA
Number of subjects: 25
Study 27846256 — intervention group
Group type: EXPERIMENTAL
Intervention: rAd5-EnvA and rAd35-EnvA (heterologous prime-boost)
Number of subjects: 25
Study 27846256 — intervention group
Group type: COMPARATOR
Intervention: rAd5-EnvA
Number of subjects: 25
Study 25010536 — intervention group
Group type: EXPERIMENTAL
Intervention: Coma Recovery Scale-Revised (CRS-R)
Number of subjects: 180
Study 23216985 — intervention group
Group type: EXPERIMENTAL
Intervention: nimesulide 100mg/day
Number of subjects: 150
Study 23216985 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin 20mg/day
Number of subjects: 150
Study 23216985 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 150
Study 20453154 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic treadmill exercise (T-EX) therapy for 3 to 6 months
Number of subjects: 52
Study 20453154 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic treadmill exercise (T-EX) therapy
Number of subjects: 52
Study 19089281 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin
Number of subjects: 0
Study 19089281 — intervention group
Group type: EXPERIMENTAL
Intervention: Poly-acid-modified composite resin
Number of subjects: 0
Study 19089281 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomer
Number of subjects: 0
Study 19089281 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional glass-ionomer
Number of subjects: 0
Study 19089281 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional composite resin
Number of subjects: 0
Study 19089281 — intervention group
Group type: EXPERIMENTAL
Intervention: All materials
Number of subjects: 0
Study 16203842 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally appropriate home safety intervention including counseling, assessment of maternal safety practices, and provision of safety items.
Number of subjects: 82
Study 16203842 — intervention group
Group type: COMPARATOR
Intervention: Control group status
Number of subjects: 82
Study 12851127 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum constriction device (VCD) with couples psychotherapy
Number of subjects: 45
Study 12851127 — intervention group
Group type: COMPARATOR
Intervention: Couples psychotherapy without VCD
Number of subjects: 45
Study 10680455 — intervention group
Group type: EXPERIMENTAL
Intervention: Squamous cell carcinoma antigen (SCC) in preliminary study
Number of subjects: 73
Study 10680455 — intervention group
Group type: EXPERIMENTAL
Intervention: Squamous cell carcinoma antigen (SCC) in monitoring
Number of subjects: 73
Study 10680455 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy persons)
Number of subjects: 73
Study 8947084 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational approach (nurse-conducted 5 min consultation, brochures, advice)
Number of subjects: 507
Study 8947084 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational approach
Number of subjects: 507
Study 8947084 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 507
Study 1879086 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicaprost (2.5 micrograms or 5 micrograms t.i.d.)
Number of subjects: 14
Study 1879086 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo tablets
Number of subjects: 14
Study 6751339 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (30-50 mg daily)
Number of subjects: 83
Study 6751339 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (120-200 mg daily)
Number of subjects: 83
Study 31005271 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 0
Study 31005271 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg + Ezetimibe 10 mg
Number of subjects: 0
Study 27725655 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (n=34)
Number of subjects: 73
Study 27725655 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (n=39)
Number of subjects: 73
Study 26839152 — intervention group
Group type: EXPERIMENTAL
Intervention: OFI‐ALA‐PDT
Number of subjects: 60
Study 26839152 — intervention group
Group type: COMPARATOR
Intervention: Traditional ALA‐PDT
Number of subjects: 60
Study 24833598 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (WH)
Number of subjects: 44
Study 24833598 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein protein (CAS)
Number of subjects: 44
Study 24833598 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate placebo (PLA)
Number of subjects: 44
Study 22796496 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel‐eluting balloon (PEB)
Number of subjects: 92
Study 22796496 — intervention group
Group type: COMPARATOR
Intervention: Drug-eluting stents (DES)
Number of subjects: 92
Study 22796496 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 92
Study 19250283 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 95
Study 19250283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 16999931 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital clock with five different interface modes
Number of subjects: 80
Study 15220226 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day Alendronate (ALN) for 2 years, followed by 10 mg/day for the remainder of the trial
Number of subjects: 297
Study 15220226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study 17000586 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hormone therapy (1 mg estradiol plus 0.5 mg norethisterone)
Number of subjects: 48
Study 17000586 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose hormone therapy (2 mg estradiol plus 1 mg norethisterone)
Number of subjects: 48
Study 17000586 — intervention group
Group type: COMPARATOR
Intervention: Calcium 1 mg/day (control group)
Number of subjects: 48
Study 10919731 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing tobacco
Number of subjects: 100
Study 10919731 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol drinking
Number of subjects: 100
Study 10919731 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 100
Study 10919731 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco chewing and low vegetable intake
Number of subjects: 100
Study 10919731 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol drinking and low vegetable intake
Number of subjects: 100
Study 10919731 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol drinking and low fruit intake
Number of subjects: 100
Study 8857486 — intervention group
Group type: EXPERIMENTAL
Intervention: Z-derived end-diastolic volume
Number of subjects: 115
Study 8857486 — intervention group
Group type: EXPERIMENTAL
Intervention: Z-derived stroke volume
Number of subjects: 115
Study 8857486 — intervention group
Group type: COMPARATOR
Intervention: Teichholz' M-mode volume method
Number of subjects: 115
Study 1517477 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% delmopinol hydrochloride
Number of subjects: 6
Study 1517477 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine digluconate
Number of subjects: 6
Study 6147422 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia
Number of subjects: 13
Study 6147422 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen of intramuscular morphine sulfate
Number of subjects: 13
Study 30938806 — intervention group
Group type: COMPARATOR
Intervention: Negative control (NC) diet with 1.3 g nPP/kg starter diet or 1.1 g nPP/kg grower diet
Number of subjects: 560
Study 30938806 — intervention group
Group type: EXPERIMENTAL
Intervention: NC diet with increasing levels of residual phytase C (500, 1,000, 2,000, 3,000, and 4,000 units/kg feed)
Number of subjects: 560
Study 30938806 — intervention group
Group type: COMPARATOR
Intervention: NC diet
Number of subjects: 560
Study 30938806 — intervention group
Group type: EXPERIMENTAL
Intervention: NC diet with increasing residual superdoses of phytase C
Number of subjects: 560
Study 30938806 — intervention group
Group type: COMPARATOR
Intervention: NC treatment
Number of subjects: 560
Study 29954702 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS treatment
Number of subjects: 0
Study 29954702 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS treatment
Number of subjects: 0
Study 27756288 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application for learning palpation and ultrasound skills
Number of subjects: 49
Study 27756288 — intervention group
Group type: COMPARATOR
Intervention: Traditional learning materials
Number of subjects: 49
Study 24122242 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 100
Study 24122242 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 100
Study 24122242 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (colon cancer subgroup)
Number of subjects: 100
Study 24122242 — intervention group
Group type: COMPARATOR
Intervention: Open surgery (colon cancer subgroup)
Number of subjects: 100
Study 22317952 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 100 mg/m(2) every 3 weeks (C)
Number of subjects: 52
Study 22317952 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m(2) IV on day 1 and gemcitabine 1250 mg/m(2) on days 1 and 8 every 3 weeks (CG)
Number of subjects: 52
Study 19011374 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap-IPV after Td-IPV
Number of subjects: 500
Study 19011374 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by Tdap-IPV
Number of subjects: 500
Study 17199721 — intervention group
Group type: EXPERIMENTAL
Intervention: LC n‐3 PUFA supplementation for 12 weeks
Number of subjects: 30
Study 16333765 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine treatment in subclinical hypothyroidism
Number of subjects: 161
Study 16333765 — intervention group
Group type: COMPARATOR
Intervention: Hyperthyroid patients
Number of subjects: 161
Study 16333765 — intervention group
Group type: COMPARATOR
Intervention: Overt hypothyroidism
Number of subjects: 161
Study 16333765 — intervention group
Group type: COMPARATOR
Intervention: Subclinical and overt hypothyroid subjects
Number of subjects: 161
Study 11997413 — intervention group
Group type: EXPERIMENTAL
Intervention: Nominal output pacing treatment
Number of subjects: 15
Study 11997413 — intervention group
Group type: COMPARATOR
Intervention: Sham pacing treatment
Number of subjects: 15
Study 10531890 — intervention group
Group type: EXPERIMENTAL
Intervention: audiotaped lullabies during immunizations
Number of subjects: 99
Study 10531890 — intervention group
Group type: COMPARATOR
Intervention: no intervention (control group)
Number of subjects: 99
Study 7632811 — intervention group
Group type: EXPERIMENTAL
Intervention: rHu-EPO at an initial dosage of 150 units/kg body weight three times a week, increased to 300 units/kg from the sixth week to the end of the 24-week study
Number of subjects: 54
Study 7632811 — intervention group
Group type: EXPERIMENTAL
Intervention: rHu-EPO
Number of subjects: 54
Study 7632811 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 54
Study 7632811 — intervention group
Group type: EXPERIMENTAL
Intervention: rHu-EPO combined with alpha-interferon (alpha-IFN)
Number of subjects: 54
Study 7632811 — intervention group
Group type: COMPARATOR
Intervention: rHu-EPO-untreated patients undergoing alpha-IFN + VMCP combined therapy
Number of subjects: 54
Study 7632811 — intervention group
Group type: COMPARATOR
Intervention: rHu-EPO-treated patients not receiving alpha-IFN
Number of subjects: 54
Study 31928890 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% isopropyl alcohol (IPA) for 5, 10, or 15 seconds
Number of subjects: 300
Study 31928890 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate (CHG) in 70% IPA for 5, 10, or 15 seconds
Number of subjects: 300
Study 30564936 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program (unsupervised walking, stationary bike, swimming, resistance exercise DVDs, pedometer, exercise log)
Number of subjects: 71
Study 30564936 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Number of subjects: 71
Study 30564936 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study 28687322 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemically modified tetracycline (CMT, incyclinide)
Number of subjects: 0
Study 28687322 — intervention group
Group type: COMPARATOR
Intervention: Placebo Control
Number of subjects: 0
Study 25518813 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive periodontal therapy during pregnancy
Number of subjects: 109
Study 25518813 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive periodontal therapy after delivery
Number of subjects: 109
Study 23223803 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 2 months
Number of subjects: 21
Study 23223803 — intervention group
Group type: COMPARATOR
Intervention: Healthy comparison subjects (control group)
Number of subjects: 21
Study 21490090 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 31
Study 21490090 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 31
Study 19734396 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon capsules, 1g daily for 90 days
Number of subjects: 109
Study 19734396 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 109
Study 16955282 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 5 mg
Number of subjects: 25
Study 16955282 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg
Number of subjects: 25
Study 16955282 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg
Number of subjects: 25
Study 16955282 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 10 mg
Number of subjects: 25
Study 16955282 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg
Number of subjects: 25
Study 16955282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 15471755 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet questionnaires
Number of subjects: 397
Study 15471755 — intervention group
Group type: COMPARATOR
Intervention: Mailed questionnaires
Number of subjects: 397
Study 11239185 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroprotective drugs
Number of subjects: 0
Study 11239185 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum clinically important differences
Number of subjects: 0
Study 11239185 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidemiological and cost-effectiveness models
Number of subjects: 0
Study 9239588 — intervention group
Group type: EXPERIMENTAL
Intervention: Convection cooling (CC)
Number of subjects: 20
Study 9239588 — intervention group
Group type: COMPARATOR
Intervention: Traditional conduction cooling (TC)
Number of subjects: 20
Study 8255984 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (8g/70kg/day)
Number of subjects: 18
Study 8255984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18